Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$14MCash on Hand
23.5mo Cash Runway
Follow EVAX by emailGet an email when EVAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EVAX, unsubscribe in one click. Privacy
📣 What EVAX Says Is Next
the end of the year · “In parallel with preclinical studies, we are preparing the regulatory filing for clinical testing of EVX-04, which is expected to be submitted before the end of the year.”
Company press release, Aug 20, 2026 · SEC filing
second half of 2026 · “Evaxion plans to submit a clinical trial application in the second half of 2026.”
Company press release, May 12, 2026 · SEC filing
second half of 2026 · “We expect to present this data in the second half of 2026.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Evaxion set its 2027 financial calendar: full year 2026 results and business update on March 4, 2027, annual general meeting on April 29, 2027, and quarterly business updates and results on May 4, August 19 and November 18, 2027. Form 6-K · SEC filing · Press release
Nov 9, 2026 ·
Regulatory Evaxion filed an amendment to its Form F-1 registration statement for the possible resale by the European Investment Bank of shares issuable on exercise of warrants from the July 2025 debt settlement. The company is not raising capital and will receive no proceeds from the resale. Form 6-K · SEC filing · Press release
Nov 6, 2026 ·
Clinical trial Evaxion presented new phase 2 biomarker data for personalized cancer vaccine EVX-01 in advanced melanoma, showing neoantigen-specific T-cells detected directly ex vivo and a significant association (p<0.001) between AI-Immunology predictions and actual T-cell responses. Form 6-K · SEC filing · Press release
Nov 4, 2026 ·
Financing Evaxion sold 201,198 ADSs in an at-the-market offering on Oct 19-21, 2026, at an average of USD 3.9714 per ADS, for net proceeds of about $775,068. Share capital rose to nominal DKK 115,283,514 and the Articles of Association were amended. Form 6-K · SEC filing
Nov 4, 2026 ·
Evaxion will present new target validation data for its off-the-shelf AML therapeutic vaccine EVX-04 in a poster at the ASH 2026 Meeting in New Orleans on December 13, 2026. The data show broad patient coverage, conserved target expression and ERV-specific T-cell responses in humanized mice. Form 6-K · SEC filing · Press release
Nov 3, 2026 ·
Clinical trial Evaxion will present new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 plus pembrolizumab in advanced melanoma at the SITC 2026 Annual Meeting, in an oral session on November 6 and a poster session on November 7. The earlier two-year trial data showed a 75% objective response rate. Form 6-K · SEC filing · Press release
Oct 30, 2026 ·
Evaxion received the 2026 International Prix Galien Award for AI-Immunology as best digital health solution, the first win by a Danish company. The award follows earlier Prix Galien honors in June 2026 and December 2025. The filing reports no new trial data, financing or deal terms. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Clinical trial Evaxion reported three-year Phase 2 data for personalized cancer vaccine EVX-01 in advanced melanoma: an immune response in all patients, with 89% of vaccine neoantigens generating specific T-cell responses. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · Phase 2 · Results Expected · A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not EVAX's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
EVAX holds $14M in cash and short-term investments and burns about $1.8M/quarter from operations,
an estimated runway of 23.5 months at that rate (BioRadar estimate, not company guidance).
Share count 417,010,756 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full EVAX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVAX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.